We are pleased to announce a new cross-journal thematic series on ‘’Artificial intelligence in Cancer imaging and diagnosis" to help bring together the latest research on the application of artificial intelligence in this field. Please click here for more information about this series.
The thematic series is now open for submission of original research and review articles. Please click here to submit your manuscript to this series.
Call for papers on artificial intelligence
Featured Review: iRECIST: how to do it
Immune-checkpoint inhibitors represent one of the most important therapy advancements in modern oncology. They are currently used for treatment of multiple malignant diseases especially at advanced, metastatic stages which were poorly therapeutically accessible in the past. A challenging aspect of these immunotherapies is that they may show atypical therapy response patterns such as pseudoprogression and demonstrate a different imaging spectrum of adverse reactions, both of which are crucial for radiologists to understand.
In this review article, Thorsten Persigehl, Simon Lennartz & Lawrence H. Schwartz provide guidance for response assessment of oncologic patients under immunotherapy based on iRECIST criteria.
Impact of COVID-19 on journal operations
As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
We are trying our best to work through this crisis as efficiently and effectively as possible and thank you for your support and patience during these challenging times.
Thumbnail image by Felipe Esquivel Reed, used under Creative Commons Attribution-Share Alike 4.0 license.
Featured: How I read Cancer Imaging Studies: The Master Class Series
Surprisingly, in contrast to the literature regarding the outcomes of imaging, the methods that underpin the generation of an imaging report and how to communicate the findings cogently to referring clinicians remain something of a ‘black box'. In this thematic series, experts across various modalities detail their approach to reporting scans in particular disease settings.
Please click here to visit the series collection page.
Interested in being a peer reviewer?
Cancer Imaging invites you to join our expert team of reviewers in assessing manuscripts. For consideration, please send a copy of your CV along with keywords and expertise to the Journal Editor.
APC discount for ICIS Members
If you are a member of the International Cancer Imaging Society (ICIS), you can receive a 20% article processing charge (APC) discount for publishing in Cancer Imaging. Please email the Journal Editor for details.
Top Cited Article of 2019
We are delighted to announce that “Most-enhancing tumor volume by MRI radiomics predicts recurrence-free survival “early on” in neoadjuvant treatment of breast cancer” was the top cited article published in Cancer Imaging of 2019.
Congratulations to all of the authors involved with this research: Karen Drukker, Hui Li, Natalia Antropova, Alexandra Edwards, John Papaioannou and Maryellen L. Giger.
Editors-in-Chief
Prof Rodney Hicks, The Peter MacCallum Cancer Centre, Australia
Assoc. Prof Annick Van den Abbeele, Dana-Farber Cancer Institute, USA
Aims and scope
Cancer Imaging is an open access, peer-reviewed journal publishing original articles, reviews and editorials written by expert international radiologists working in oncology.
The journal encompasses CT, MR, PET, ultrasound, radionuclide and multimodal imaging in all kinds of malignant tumours, plus new developments, techniques and innovations.
Please click here for more information.
What is trending?
Click here to see which articles published in Cancer Imaging have been shared the most in the past three months.
Articles
-
-
Follow-up schedule for initial recurrent hepatocellular carcinoma after ablation based on risk classification
-
Ventricular apparent diffusion coefficient measurements in patients with neoplastic leptomeningeal disease
-
MRI features predict microvascular invasion in intrahepatic cholangiocarcinoma
-
Improving MR sequence of 18F-FDG PET/MR for diagnosing and staging gastric Cancer: a comparison study to 18F-FDG PET/CT
-
How We Read Oncologic FDG PET/CT
-
Prostate MRI based on PI-RADS version 2: how we review and report
-
Chest-abdomen-pelvis CT for staging in cancer patients: dose effectiveness and image quality using automated attenuation-based tube potential selection
-
MRI of endometrium cancer – how we do it
-
Cross-sectional imaging in cancers of the head and neck: how we review and report
Editor's quote
A major focus of Prof Rodney Hicks' (Co-Editor-in-Chief of Cancer Imaging) clinical research has been to assess the impact of PET on patient management and prognostic stratification.
"A few years ago I changed the name of my department from Diagnostic Imaging to Cancer Imaging since it occurred to me that little of what we do is diagnostic. Increasingly, the role of imaging in cancer is in selecting, planning and monitoring treatment. The challenge of imaging science is to establish our techniques as prognostic and predictive biomarkers and to show that our results improve patient outcomes"
Prof Rodney Hicks, Co-Editor-in-Chief, Cancer Imaging
-
Official journal of
-
Cancer Imaging is the official journal of the International Cancer Imaging Society (ICIS)
-
- Editorial Board
- Instructions for Editors
- Sign up for article alerts and news from this journal
Follow
Annual Journal Metrics
-
Speed
77 days to first decision for reviewed manuscripts only
61 days to first decision for all manuscripts
133 days from submission to acceptance
15 days from acceptance to publicationCitation Impact
2.193 - 2-year Impact Factor
2.885 - 5-year Impact Factor
1.382 - Source Normalized Impact per Paper (SNIP)
0.939 - SCImago Journal Rank (SJR)Usage
360,800 Downloads
273 Altmetric Mentions
